Compounds inhibiting LpxC in the lipid A biosynthetic pathway are promising leads for novel antibiotics against multidrug-resistant Gram-negative pathogens. We report the syntheses and structural and biochemical characterizations of LpxC inhibitors based on a diphenyl-diacetylene (1,4-diphenyl-1,3-butadiyne) threonyl-hydroxamate scaffold. These studies provide a molecular interpretation for the differential antibiotic activities of compounds with a substituted distal phenyl ring as well as the absolute stereochemical requirement at the C2, but not C3, position of the threonyl group.
Introduction
Lipid A, the hydrophobic membrane anchor of lipopolysaccharide, is the major lipid component of the outer leaflet of the outer membrane of Gram-negative bacteria. 1, 2 Because lipid A is essential for the viability of the vast majority of Gram-negative bacteria, the zinc-dependent UDP-3-O-(acyl)-N-acetylglucosamine deacetylase (LpxC), which catalyzes the first irreversible step in lipid A biosynthesis, has become an attractive target for the development of novel therapeutics for treatment of multidrug-resistant Gramnegative infections. 3 Indeed, a large number of compounds with vastly different chemical scaffolds targeting LpxC have been reported in both the scientific 4, 5 and patent [6] [7] [8] [9] [10] [11] [12] [13] [14] literature.
Among the well-characterized compounds, CHIR-090 based on the diphenyl-acetylene scaffold (Table 1) is the most potent LpxC inhibitor reported to date, and it is the first reported compound that effectively kills both Escherichia coli and Pseudomonas aeruginosa in bacterial disk diffusion assays. 15 Because P. aeruginosa is a predominant cause of morbidity and mortality in cystic fibrosis patients and can cause a variety of infections, particularly in immunosuppressed individuals, the discovery of potent antibiotic activity of CHIR-090 against P. aeruginosa has generated significant interest in further developing LpxC inhibitors as novel antibiotics for treatment of multidrug-resistant Pseudomonas and other Gram-negative infections. However, CHIR-090 is about 600-fold less effective against LpxC orthologs from the Rhizobiaceae family than against E. coli LpxC, which raises concerns surrounding rapid evolution of antibiotic resistance for CHIR-090 sensitive strains through point mutations. 16 Our recent structural and biochemical studies of the LpxC/CHIR-090 complex suggest that van der Waals (vdW) clashes between the phenyl ring distal to the hydroxamate group of CHIR-090 and LpxC residues at the substrate-binding passage result in a large decrease in CHIR-090 activity against LpxC orthologs of the Rhizobiaceae family. 17 This study has motivated us to investigate the antibiotic profiles of LpxC inhibitors based on a chemical scaffold of reduced radius, such as the diacetylene (1,3-butadiyne) backbone. Recently, we showed that the 1,4-diphenyl-1,3-butadiyne (referred to as diphenyl-diacetylene below) derived LPC-009 (Table 1) , which is one of the many structures listed in the international patent WO 2004/062601 A2, 6 effectively diminishes the resistance to CHIR-090 by 20-fold for LpxC enzymes from the Rhizobiaceae family of bacteria and enhances the antibiotic activity against E. coli and P. aeruginosa by 2-4-fold over CHIR-090. 18 Although diacetylene-based LpxC inhibitors have appeared in a number of international patents, 6, 8 there is a lack 0968-0896/$ -see front matter Ó 2010 Elsevier Ltd. All rights reserved. doi:10.1016/j.bmc.2010.12.017 of synthetic details for these compounds. The potency, spectrum of inhibition, and structure-activity relationship of these compounds have not been systematically characterized. In addition, the diphenyl-diacetylene compound LPC-009 has limited solubility in aqueous solution. In order to improve the solubility and probe the stereochemical requirement of the threonyl group of LPC-009, we have carefully selected from published patents 6,8 a set of LPC-009 amino derivatives and designed additional compounds based on structural insights from the LpxC/LPC-009 complexes. 18 These compounds were synthesized using optimized procedures. Through detailed biochemical assays and structural characterizations of these LpxC-inhibitor interactions, we reveal the molecular basis underlying the observed structure-activity relationship of LPC-009 amino derivatives as well as the stereochemical requirement of the threonyl head group.
Results

Synthesis
Synthesis of LPC-011 began with acylation of L-threonine methyl ester using sodium 4-ethynylbenzoate 1 (Scheme 1). Under modified Glaser coupling conditions, 19, 20 the resulting 4-ethynylbenzamide 2 was coupled with 4-ethynylbenzenamine to afford diacetylene methyl ester 3a. Finally, the methyl ester was converted to the corresponding hydroxamic acid (LPC-011) by treatment with hydroxylamine under basic conditions. Regioisomers LPC-012 and LPC-013 were synthesized through the same procedure. 2-Ethynylbenzenamine was very sluggish to proceed the Glaser coupling with 4-ethynylbenzamide 2; the isolated yield was only 26% even after 80 h reaction at room temperature. Elevated temperature did not improve the yield. In order to study the effect of threonyl chirality on LPC-011 inhibitory activity, three diastereoisomers of LPC-011 were synthesized (Scheme 2). For convergence of the synthesis, 4-[(4 0 -aminophenyl)buta-1,3-diyn-1-yl]benzoic acid 6 6 was prepared in four steps: Sonogashira coupling 21 of methyl 4-iodobenzoate with (trimethylsilyl)-acetylene, followed by treatment with potassium carbonate to afford methyl 4-ethynylbenzoate 4. Employing a similar procedure for 3a-c, 4 was coupled with 4-ethynylbenzenamine to give diacetylene methyl ester 5. Upon hydrolysis with NaOH, diacetylene acid 6 was obtained from 5 in 90% yield. For the preparation of allo-L-threonine methyl ester 11 with the S absolute configuration at C3 position, L-threonine methyl ester (8) was acylated with benzoyl chloride to generate N-benzoyl amino ester 9. Compound 9 was treated with thionyl chloride 17 on ice to give oxazoline 10, establishing the S absolute configuration at C5. 22, 23 Acid hydrolysis of 10 in boiling 6 N HCl aqueous solution resulted in allo-L-threonine. This compound was converted to the corresponding methyl ester hydrochloride 11 (Scheme 2). Under standard amide coupling conditions (EDC/HOBt/DIEA), 11 was reacted with diacetylene acid 6 to give diacetylene amide 7 in 90% yield. Finally, the methyl ester was converted to the corresponding hydroxamic acid (LPC-053) by treatment with hydroxylamine under basic conditions. Diastereoisomer LPC-054, which incorporates the R absolute configuration at both C2 and C3 began from D-threonine. D-Threonine was refluxed with thionyl chloride in MeOH to produce the corresponding methyl ester hydrochloride, and then coupled with diacetylene acid 6, resulting in diacetylene amide methyl ester (92% yield). Treatment with hydroxylamine under basic conditions converted the methyl ester to the corresponding hydroxamic acid LPC-054 (93% yield; Scheme 2). By employing identical procedures, enantiomer LPC-055 with 2R and 3S configurations was obtained starting from allo-D-threonine (Scheme 2). The overall yield ($48%) for the last two steps was slightly lower than for LPC-054. Neither racemization nor epimerization was observed by LC-MS or NMR during the synthesis of LPC-011-013 and 053-055 when using 25% sodium methoxide in methanol solution as the base for converting the methyl esters into the corresponding hydroxamic acids.
Structure-activity relationship
The antibiotic activities of LPC-011-013 and 053-055 were evaluated by measuring the minimum inhibitory concentrations (MICs) against wild-type E. coli (W3110), P. aeruginosa (PAO1), and modified E. coli strains with the native lpxC gene replaced by that of Rhizobium leguminosarum (W3110RL) or P. aeruginosa (W3110PA) ( Table 1) .
Amino substitution of the distal phenyl ring
In general, addition of an amino group to the distal phenyl ring of LPC-009 enhanced aqueous solubility. However, these substitutions have very different effects on antibiotic activities. The most effective compound, LPC-011 with an amino substitution at the para-position of the distal phenyl ring, shows enhancement in antibiotic activity over CHIR-090 against all of the tested bacterial strains: compared to CHIR-090, LPC-011 is roughly 7-fold more potent against wild-type E. coli W3110, 32-fold more potent against E. coli W3110RL, and $3-fold more potent against E. coli W3110PA and P. aeruginosa PAO1. These results are consistent with the notion that LpxC inhibitors with the narrow diacetylene scaffold effectively overcome the resistance mechanism observed for R. leguminosarum LpxC, 17, 18 and have a superior antibiotic profile compared to CHIR-090. Compound LPC-011 also displays enhanced antibiotic activity ($1.5-fold) toward wild-type E. coli and P. aeruginosa compared to the parent compound LPC-009. In contrast, amino substitution at the meta-position (LPC-012) has little or slightly negative effect, and amino substitution at the orthoposition (LPC-013) results in a significant decrease in antibiotic activity (>10-fold).
To probe the molecular basis for the distinct antibiotic profiles for compounds with amino substitutions at different positions (ortho, meta and para), we determined the crystal structures of E. coli LpxC in complex with the para-amino substituted compound LPC-011 and meta-amino substituted compound LPC-012 (crystallographic statistics shown in Table S1 in Supplementary data). The overall structure of E. coli LpxC in these inhibitor-bound complexes is essentially identical to that in the E. coli LpxC/LPC-009 complex: 18 the threonyl-hydroxamate head group occupies the LpxC active site, the proximal phenyl group locates at the entrance of the hydrophobic substrate-binding passage, the diacetylene group penetrates through the passage, and the distal phenyl ring interacts with a cluster of hydrophobic residues, including I198, M195, F212 and V217 in E. coli LpxC ( Fig. 1A and B). Additional electron density, which was interpreted as a buffer sulfate anion, was observed in the active site, mediating hydrogen bonds with the inhibitor threonyl group and K239 in E. coli LpxC. Of all three possible positions of the distal phenyl ring, substitution at the para-position is best tolerated, as this position remains solvent exposed and does not generate vdW clashes with nearby residues. In addition, para-amino substitution of the distal phenyl group, due to its proximity to the F212 of E. coli LpxC, likely enhances the edge-to-face p-p interaction between the distal phenyl ring of LPC-011 and F212 of E. coli LpxC, modestly increasing the activity of the para-amino compound LPC-011 relative to LPC-009 for E. coli (Fig. 1A) . To obtain more quantitative measurements of the inhibitory effect of LPC-011, we performed detailed enzyme kinetic studies. Analogous to LPC-009 but unlike the slow tight-binding inhibitor CHIR-090, Amino substitution at the meta-position generated different results for distinct LpxC orthologs. In the E. coli LpxC/LPC-012 complex, the meta-amino forms a hydrogen bond with the carbonyl oxygen of the side group of Q202 (Fig. 1B ), but this hydrogen bond apparently does not contribute significantly to the overall binding energy, as the activity of the meta-amino substituted compound is comparable to the less soluble, unsubstituted compound LPC-009.
In contrast to para-or meta-substitutions, an amino group at the ortho-position is clearly detrimental: structural modeling suggests that regardless of the orientation of the distal phenyl ring, amino substitution at the ortho-position generates vdW clashes with Q202 and F212 of E. coli LpxC and the corresponding residues in other LpxC orthologs ( Fig. 1D and E) . Consequently, the orthoamino substituted compound LPC-013 is substantially less effective than the parent compound LPC-009 for all of the bacterial strains tested (>10-fold).
Stereochemistry of the threonyl group
We also investigated the stereochemical requirement for the threonine head group in LPC-011 on its antibiotic activity using three diastereoisomers of LPC-011. The MIC results show that the S-configuration at C2 position of the threonine moiety in LPC-011 is absolutely required for effective antibiotic activity. When the absolute configuration in C2 position is inverted from S to R, the resulting (2R,3R)-diastereomer LPC-054 and (2R,3S)-enantiomer LPC-055 exhibited significantly decreased activity compared to LPC-011 (over 100-fold for E. coli). On the other hand, the absolute configuration at C3 position is less critical than the stereochemistry at the C2 position. For example, the (2S,3S)-diastereomer LPC-053 showed only a slight decrease (1.6-3.2-fold) in antibiotic activity compared to the (2S,3R)-diastereomer LPC-011 against all of tested bacterial strains. The nearly identical activity for the C3 diastereomeric compound LPC-053 is surprising, as the methyl group of LPC-011 forms a critical vdW interaction with the highly conserved F192 in E. coli LpxC and the hydroxyl group of LPC-011 participates in hydrogen bonds with K239 and H265. To seek a molecular understanding of the binding mode of the C3-S diastereometeric compound LPC-053, we determined its complex structure with E. coli LpxC ( Fig. 2A , crystallographic statistics shown in Table S1 in Supplementary data). The structure reveals intact vdW interactions between the methyl group of LPC-053 and F192, highlighting their significant energetic contribution to the binding affinity. In contrast to the C3-R compound LPC-011, the hydroxyl group in LPC-053 points away from the active site and is unable to form direct hydrogen bonds with K239 and H265. Interestingly, the loss of hydrogen bonds in LPC-011 (2S,3R) is compensated by the formation of a water-mediated hydrogen bond between the hydroxyl group in LPC-053 (2S,3S) and the carbonyl oxygen of F192 ( Fig. 2A) . Similar to the LPC-011 and LPC-012 complex, additional density was observed in the active site, which was interpreted as a sulfate anion from the buffer. The energetic contribution of the sulfate group to LPC-053 binding to LpxC is unclear, but the sulfate group is well-positioned to form hydrogen bonds with the hydroxyl group of LPC-053 and K239 of E. coli LpxC. Thus the change of the stereochemistry at the C3 position only has a limited effect (<3.5-fold) on the overall antibiotic activity. In contrast, the stereochemistry at the C2 position is critical: with the same overall binding mode, alteration of the C2 stereochemistry from S to Rregardless of the rotameric state of the threonyl side-chain-generates vdW clashes with residues (such as C63 in E. coli LpxC) in the Insert I loop (Fig. 2B and C) , resulting in significantly reduced antibiotic activities for compounds LPC-054 and LPC-055.
Discussion and conclusion
Most of the LpxC inhibitors reported in the literature are limited by their spectrum of antibiotic activities. The structural prediction and experimental validation of broad-spectrum antibiotic activities of LpxC inhibitors based on the diacetylene moiety-a chemical scaffold initially reported in the international patent WO 2004/ 062601 A2-are an important step forward in the search for better antibiotics targeting LpxC. To improve the solubility of LPC-009 in aqueous solution and to probe the stereochemical requirement of the threonyl group, we investigated the structures and antibiotic profiles of LPC-009 derivatives. Although all three amino substituents of the distal phenyl ring (LPC-011-013) have improved solubility in aqueous solution, they have very different antibiotic profiles. The para-amino substituent LPC-011 slightly enhances the antibiotic activity of the parent compound LPC-009, and has a 2.7-fold lower K I value than that of LPC-009 against E. coli LpxC. The para-position is largely exposed to solvent, suggesting that even more extensive functionality can be tolerated. Therefore, it might be possible to replace the para-amino group with a fluorophore or an azide group without significantly affecting its antibiotic activity. This may allow the development of fluorescence-based inhibitor binding assays or new tools based on click chemistry via Cu(I)-catalyzed azide-alkyne cycloaddition 24 for affinity purification and identification of human metalloproteins that tightly associate with LpxC inhibitors in cells-a particular concern for the unintended off-target activity of hydroxamatecontaining compounds. Stereochemistry is an important factor of inhibitor design. We show that the R-stereoisomer at the C2 position of the threonyl group is detrimental to the antibiotic profiles of LPC-011 derivatives. In contrast, the chirality at the C3 position of the threonyl group is less stringent, and compounds with either S-or R-configurations at the C3 position show similar antibiotic activities for tested bacterial strains. Our structural investigation reveals an invariant threonyl methyl-F192 interaction regardless of the stereochemistry at the C3 position. However, the loss of favorable hydrogen bonds between the hydroxyl group in the 3R configuration of LPC-011 and K239 and H265 of E. coli LpxC is compensated by a water-mediated hydrogen bond with the carbonyl group of F192 of E. coli LpxC involving the same hydroxyl group in the 3S configuration of LPC-053 pointing away from the active site toward the solvent. Previous structural studies of the LpxC/UDP complex have revealed a UDP-binding pocket that is located adjacent to the active site occupied by the threonyl head group of CHIR-090. 17, 25, 26 Recently, uridine-based compounds have been shown to inhibit LpxC in vitro, presumably by competing for the same UDP-binding pocket with the LpxC substrate UDP-3-O-(acyl)-N-acetylglucosamine. 27 Because the hydroxyl group in the 3S compound LPC-053 is solvent exposed, it may be a convenient functional group for further derivatization to extend the current compound binding interface to the adjacent UDP-binding pocket and generate more potent inhibitors based on the well-known ligand additivity effect. 28 
Experimental section
LC/MS analysis was conducted on an Agilent 1200 HPLC with a quadrupole mass analyzer. LC chromatography used an Agilent XDB-C18 column (4.6 Â 50 mm, 1.8 lm) with a water/acetonitrile (each with 0.2% (v/v) formic acid) gradient at a flow rate of 0.5 mL/min. HRMS analyses were performed at the Duke MS Center. Proton ( 1 H) and carbon ( 13 C) NMR spectra were recorded at 300 and 75 MHz, respectively, on a Varian spectrometer. Column chromatography was conducted using either silica gel (Silicycle 40-64 lm) or prepacked RediSep columns (Teledyne Isco Inc., Lincoln, NE) on an Isco CombiFlash Rf instrument. All moisture-sensitive reactions were carried out using dry solvents and under a slight pressure of ultra-pure argon. Glassware was dried in an oven at 140°C for at least 12 h prior to use, and then assembled quickly while hot, sealed with rubber septa, and allowed to cool under a stream of argon. Reactions were stirred magnetically using Teflon-coated magnetic stirring bars. Commercially available disposable syringes were used for transferring reagents and solvents.
Methyl (2S,3R)-2-[(4 0 -ethynylphenyl)formamido]-3-hydroxybutanoate (2)
To a stirred mixture of sodium 4-ethynylbenzoate 1 (2.52 g, 15 mmol) and L-threonine methyl ester hydrochloride (3.05 g, 18 mmol, 1.2 equiv) in anhydrous DMF (100 mL) was added N-ethyl-N 0 -(3-dimethylaminopropyl) carbodiimide hydrochloride (EDCÁHCl) (3.45 g 18 mmol, 1.2 equiv) and 1-hydroxybenzotriazole hydrate (HOBt) (2.45 g 18 mmol, 1.2 equiv) at room temperature. The mixture was cooled in an ice-bath, and diisopropylethylamine (DIEA) (10.45 mL, 60 mmol, 4.0 equiv) was added. The whole reaction mixture was stirred under argon at 0°C for 1 h, then allowed to warm to ambient temperature, and the stirring was continued for additional 20 h. The resulting yellow solution was evaporated to dryness under reduced pressure, and the resulting residue was treated with water (100 mL) and extracted with EtOAc (3 Â 100 mL). The combined extracts were washed with 1 N HCl (2 Â 70 mL) and brine (100 mL), and dried (anhydrous Na 2 SO 4 ). Evaporation of the solvent afforded the crude product (3.5 g), which was crystallized from EtOAc/hexane to give 2 (1.9 g, 48% yield) as light yellow crystal. 
General procedure for Glaser coupling of 4-ethynylbenzamide 2 with ethynylbenzenamine
Copper(II) acetate (0.36 g, 2 mmol, 2.0 equiv) was added at room temperature to a stirred solution of 2 (0.26 g, 1 mmol) and substituted acetylene (5 mmol, 5 equiv) dissolved in anhydrous pyridine (4 mL) and MeOH (4 mL), and the reaction mixture was stirred at room temperature for 18 h (80 h for 3-ethynylbenzenamine and 2-ethynylbenzenamine). The resulting blue solution was concentrated to dryness with a rotavapor, and the residue was treated with water (50 mL) and extracted with EtOAc (3 Â 50 mL). The combined organic extracts were washed with water (50 mL) and brine (50 mL), and dried (anhydrous Na 2 SO 4 ). The crude product was purified by the CombiFlash system (eluting with 50-75% EtOAc in hexane) to afford diacetylene methyl ester 3a-c as yellow solid. 4.3. General procedure for preparing hydroxamic acids (LPC-011, 012, 013) from the corresponding methyl esters 3a-c
Methyl (2S,3R)-2-{4
To an ice-cold solution of 3 (120 mg, 0.32 mmol) dissolved in anhydrous MeOH (1.5 mL) and THF (1.5 mL) was added hydroxylamine hydrochloride (110 mg, 1.60 mmol, 5 equiv) followed by 25% sodium methoxide in methanol solution (0.53 mL, 2.20 mmol, 7 equiv). The reaction mixture was stirred under argon at 0°C for 2 h, then allowed to warm to ambient temperature and stirring was continued overnight (16 h). The resulting yellow suspension was concentrated to dryness with a rotavapor, and the residue was treated water (50 mL). The mixture was extracted with EtOAc (3 Â 50 mL). The combined organic layers were washed with brine (30 mL) and dried. Evaporation of the solvent afforded the crude product, which was purified by CombiFlash (eluting with MeOH in DCM 7-10%) to afford hydroxamic acid as yellow solid. 
(2S,3R)-2-{4
0 -[(3 00 -Aminophenyl)buta-1 0 ,3 0 -diynyl]benz- amido}-1,3-dihydroxy-).
General procedure for synthesis of LPC-053, 054 and 055
To a stirred mixture of acid 6 (120 mg, 0.46 mmol) and allo-L-threonine methyl ester hydrochloride 11 (94 mg, 0.55 mmol, 1.2 equiv) in anhydrous DMF (5 mL) was added EDCÁHCl (106 mg 0.55 mmol, 1.2 equiv), HOBt (75 mg, 0.55 mmol, 1.2 equiv) at room temperature. The mixture was chilled to 0°C with an ice-bath, and DIEA (0.32 mL, 1.84 mmol, 4 equiv) was added. The reaction mixture was stirred under argon at 0°C for 1 h, then allowed to warm to ambient temperature with the stirring continued for additional 18 h. The resulting yellow solution was condensed to dryness with a rotavapor, and the residue was treated with water (20 mL), extracted with EtOAc (3 Â 50 mL). The combined extracts were washed with brine (40 mL), and dried. Evaporation of the solvent afforded the crude product, which was purified by CombiFlash To an ice-cold solution of 7 (100 mg, 0.26 mmol) dissolved in anhydrous MeOH (1 mL) and THF (1 mL) was added hydroxylamine hydrochloride (92 mg, 1.33 mmol, 5 equiv) followed by 25% sodium methoxide in methanol solution (0.47 mL, 2.0 mmol, 7.5 equiv). The reaction mixture was stirred under argon at 0°C for 2 h, then allowed to warm to ambient temperature with the stirring continued overnight (14 h). The resulting yellow suspension was condensed to dryness with a rotavapor, and the residue was treated water (20 mL), extracted with EtOAc (3 Â 50 mL). The combined extracts were washed with brine (20 mL), and dried. Evaporation of the solvent afforded the crude product, which was purified by CombiFlash (eluting with 1-8% MeOH in DCM) to afford (2S,3S)-2-{4 4.5. Construction of E. coli W3110PA P. aeruginosa lpxC was used to replace E. coli chromosomal lpxC. A linear PCR product containing the P. aeruginosa lpxC with flanking sequences complementary to the upstream 5 0 region of E. coli lpxC and to the downstream 3 0 region of E. coli lpxC, was amplified from a plasmid carrying P. aeruginosa lpxC using primers pa-LpxC-5 0 and pa-LpxC-3 0 (Table S2 ). The PCR product was gel purified and electroporated into E. coli DY330 cells, which carry k-red recombinases. While DY330 cannot survive on the LB/agar plate supplemented with 15 lg/mL of L-161,240, cells wherein E. coli lpxC replaced with P. aeruginosa lpxC can survive on this media. Transformants were therefore selected directly using L-161,240. Genomic DNA from resistant colonies was isolated, and the region around lpxC was amplified with primers 300-up-lpxC and 300-down-lpxC and sequenced with primers paLpxC-361-5 0 and paLpxC-581-3 0 (Table S2) . One clone in which P. aeruginosa lpxC had replaced chromosomal E. coli lpxC was selected and grown at 30°C. This strain was used to generate P1vir lysate, which was used to transduce chromosomal P. aeruginosa lpxC into the chromosome of E. coli W3110. Transduced cells were plated on LB/agar containing 15 lg/mL of L-161,240 and 10 mM sodium citrate. The resulting colonies were purified three times on this media. Genomic DNA from resistant colonies was isolated, and the region around lpxC was amplified with the primers 300-up-lpxC and 300-down-lpxC, and sequenced with paLpxC-361-5 0 and paLpxC-581-3 0 . The colony that harbored the P. aeruginosa lpxC knock-in was named as W3110PA. and K I values were performed as described previously, 18 except that the LPC-011 concentrations were varied from 0.8 pM to 51 nM. MICs were determined according to the NCCLS protocol adapted to 96-well plates and LB media in the presence of 5% DMSO as described previously.
18,31
X-ray crystallography
Purified E. coli LpxC (1-300) samples at a final concentration of 10 mg/mL were mixed with 4-fold molar excess of individual compounds. Crystals of E. coli LpxC in complex with LPC-011, LPC-012 or LPC-053 were obtained using the hanging drop vapor diffusion method at 4°C in solutions containing 0.1 M HEPES pH 7.5, 1.5-1.7 M Li 2 SO 4 and 10 mM DTT. The crystals were cryoprotected with perfluoropolyether (PFO-X175/08) before being flash-frozen in liquid nitrogen. Diffraction data were collected in-house at 100 K using a Rigaku MicroMax-007 HF rotating anode generator and R-Axis IV++ detector. X-ray diffraction data were processed with HKL2000. 32 Molecular replacement with phaser was used to obtain the initial phases of the LpxC-inhibitor complex structures. 33 The structure of the E. coli LpxC/LPC-009 complex (PDB entry 3P3E) was used as the search model. Water molecules were added using phenix 34 and verified with coot. 35 Additional electron density at the protein packing interface is observed in all three E. coli LpxC-inhibitor complex crystals. Because this electron density cannot be fitted with the protein or the inhibitor, it likely represents a buffer molecule (e.g., HEPES) or impurity from the chemical synthesis. The final models were obtained after iterative cycles of manual model building with coot and refinement using phenix. molprobity 36 was used to evaluate the quality of the refined structures. The statistics for the LpxC-inhibitor complexes are shown in Table S1 . Structures factors and coordinates for E. coli LpxC in complex with LPC-011, LPC-012, and LPC-053 have been deposited in the RCSB Protein Data Bank with the accession codes 3PS1, 3PS2, 3PS3, respectively.
